Generic Pharmaceutical Substitution Management

The contract requires the provision of FDA 'A' rated generic pharmaceuticals to serve as therapeutically equivalent substitutes for brand-name drugs, ensuring cost-effective and clinically appropriate medication alternatives across military healthcare systems. Substitution must be implemented wherever clinically justified and acceptable, with documented exceptions permitted only when therapeutic equivalence cannot be established or patient safety necessitates continued use of the branded agent. All submissions must adhere to strict regulatory standards and demonstrate full compliance with FDA bioequivalence requirements for 'A' rated products. Performance is expected to center in San Antonio, Texas, with all activities aligned to support the Defense Health Agency’s mission under the Department of Defense. The contract is classified as a subcontract under the NAICS code 424210 for Pharmaceutical and Bulk Drug Merchant Wholesalers and is open for response until June 29, 2026. Suppliers must be capable of maintaining consistent, reliable supply chains for generic medications while providing clinical documentation to support non-substitution decisions, ensuring continuity of care for service members and their families without compromising therapeutic outcomes or regulatory compliance.